Lawmakers Anxious Over Cost of Proposed Change in Drug Rebates

Aug. 9, 2018, 7:01 PM

Lawmakers are concerned the financial impact of a proposed change to drug rebates isn’t being carefully considered by regulatory reviewers.

Orrin Hatch (R-Utah), head of the Senate Finance Committee, and Greg Walden (R-Ore.), head of the House Energy and Commerce Committee, sent a letter Aug. 9 asking the Office of Management and Budget to ensure it fully considers the economic impact a change in the drug rebate system could have on the country.

It isn’t clear exactly what’s in the Health and Human Services Department’s proposed rule, which is for pharmacy benefit managers and others and is titled “Removal 0f ...

To read the full article log in.

Learn more about a Bloomberg Law subscription.